Research Findings Suggest Potent, Broad-Spectrum Antiviral Activity For Vertex's Investigational IMPDH Inhibitor VX-497

The investigational drug VX-497 may have potent, broad-spectrum antiviral activity, according to laboratory results presented by scientists from Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) at the 12th International Conference on Antiviral Research held this week in Jerusalem, Israel. VX-497's activity against viruses in cell culture was compared to that of the antiviral compound ribavirin, both alone and in combination with interferonalpha. Vertex is evaluating VX-497 in Phase II clinical trials for HCV infection and as an immunosuppressant for psoriasis.

VX-497 is a potent inhibitor of inosine monophosphate dehydrogenase (IMPDH), a human enzyme that is essential for the de novo production of guanosine nucleotides (for example, GTP)-one of the building blocks of RNA and DNA. Inhibition of IMPDH may be an effective strategy for blocking the rapid proliferation (growth) of certain cell types which uniquely depend upon this de novo pathway--such as B and T lymphocytes--as well as blocking viral replication, which is often more dependent on the de novo pathway than on the alternative "salvage" pathway of nucleotide biosynthesis used by most human cells.

In one study comparing the activity of VX-497 versus ribavirin against selected DNA and RNA viruses in vitro, VX-497 was found to be 15-to 186-fold more potent than ribavirin against hepatitis B virus, human cytomegalovirus, respiratory syncytial virus, herpes simplex virus type 1, parainfluenza-3 virus, and Venezuelan equine encephalitis virus. Preliminary data suggests VX-497 may be more potent than ribavirin against bovine viral diarrhea virus and as potent as ribavirin against dengue virus.

In another study, using cells infected with encephalomyocarditis virus (EMCV), VX-497 was shown to have 15-to 40-fold more potent antiviral activity in combination with interferon-alpha, when compared to a combination of ribavirin plus interferon-alpha. Ribavirin is marketed in the

Contact: Michele Karpf
Vertex Pharmaceuticals

Page: 1 2

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Schepens Eye Research Institute receives Roadmap grant to develop center for curing eye diseases
4. Researchers identify protein promoting vascular tumor growth
5. Researchers devise potent new tools to curb ivory poaching
6. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
7. Researchers ID chlorophyll-regulating gene
8. Environmental issues center of Inland Northwest Research Alliance 4th Annual Symposium
9. Research suggests new avenue for stopping, preventing colon cancer
10. Researchers develop fast track way to discover how cells are regulated
11. Research on carbohydrate metabolism receives historical recognition

Post Your Comments:

(Date:3/18/2019)... ... 18, 2019 , ... Early engagement not only improves and ... improves participation by better balancing scientific objectives with patient goals. , Reaching out ... entire process from development to market. Involving these groups in this manner ensures ...
(Date:3/14/2019)... ... ... Highmark Health’s VITAL Innovation Platform has been named the winner in the “Corporate Innovation” ... top honors in the awards. Winners were announced at an event on March 12 ... May 10 that also raises funds for Carnegie Science Center programs that inspire young ...
(Date:3/12/2019)... ... March 12, 2019 , ... FEITIAN Technologies ... all-in-one smart cards, announced today the launch of two new payment card types ... Dynamic CVV Payment cards. These advanced technologies will help all elements of the ...
Breaking Biology News(10 mins):
(Date:3/14/2019)... ... March 14, 2019 , ... ... announcing that its Canadian partner, the Eye Machine Canada Inc., had been given ... pioneering technology for treating Age-Related Macular Degeneration (AMD). , The previous month, the ...
(Date:3/12/2019)... , ... March 11, 2019 , ... ... hospital system in Colorado, and among the first in the nation, to offer ... lab draws, IV placement and overall degree to which staff showed compassion jumped ...
(Date:3/9/2019)... (PRWEB) , ... March 07, 2019 , ... ... is a pioneer in the development and commercialization of high performance, cutting-edge cell ... a leading European CRO with GLP-certified expertise in cardiovascular pharmacology and electrophysiology, are ...
(Date:3/4/2019)... ... 2019 , ... Stay on top of current hot topics through free webinars presented by leading ... so be sure to register today to save your place! Participate in the discussion and ... , CLINICAL TRIALS, , March 20 – Implementing BYOD Across Phase ...
Breaking Biology Technology:
Cached News: